Effectiveness and Protection Duration of Covid-19 Vaccines and Previous Infection Against Any SARS-CoV-2 Infection in Young Adults

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Jul 8

PMID 35803915

Authors

Lior Rennert

Zichen Ma

Christopher S McMahan

Delphine Dean

Affiliations

Soon will be listed here.

Abstract

Data on effectiveness and protection duration of Covid-19 vaccines and previous infection against general SARS-CoV-2 infection in general populations are limited. Here we evaluate protection from Covid-19 vaccination (primary series) and previous infection in 21,261 university students undergoing repeated surveillance testing between 8/8/2021-12/04/2021, during which B.1.617 (delta) was the dominant SARS-CoV-2 variant. Estimated mRNA-1273, BNT162b2, and AD26.COV2.S effectiveness against any SARS-CoV-2 infection is 75.4% (95% CI: 70.5-79.5), 65.7% (95% CI: 61.1-69.8), and 42.8% (95% CI: 26.1-55.8), respectively. Among previously infected individuals, protection is 72.9% when unvaccinated (95% CI: 66.1-78.4) and increased by 22.1% with full vaccination (95% CI: 15.8-28.7). Statistically significant decline in protection is observed for mRNA-1273 (P < .001), BNT162b2 (P < .001), but not Ad26.CoV2.S (P = 0.40) or previous infection (P = 0.12). mRNA vaccine protection dropped 29.7% (95% CI: 17.9-41.6) six months post- vaccination, from 83.2% to 53.5%. We conclude that the 2-dose mRNA vaccine series initially offers strong protection against general SARS-CoV-2 infection caused by the delta variant in young adults, but protection substantially decreases over time. These findings indicate that vaccinated individuals may still contribute to community spread. While previous SARS-CoV-2 infection consistently provides moderately strong protection against repeat infection from delta, vaccination yields a substantial increase in protection.

Citing Articles

Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality.

Jiang J, Lam K, Lau E, Yin G, Lin Y, Cowling B Sci Rep. 2025; 15(1):5640.

PMID: 39955370 PMC: 11830013. DOI: 10.1038/s41598-025-89043-8.

Strength and durability of indirect protection against SARS-CoV-2 infection through vaccine and infection-acquired immunity.

Tan S, Rodriguez-Barraquer I, Kwan A, Blumberg S, Park H, Hutchinson J Nat Commun. 2025; 16(1):1090.

PMID: 39881133 PMC: 11779853. DOI: 10.1038/s41467-024-55029-9.

The hybrid lipoplex induces cytoskeletal rearrangement via autophagy/RhoA signaling pathway for enhanced anticancer gene therapy.

Hu X, Wang Y, Wang R, Pu Y, Jin R, Nie Y Nat Commun. 2025; 16(1):339.

PMID: 39747218 PMC: 11696071. DOI: 10.1038/s41467-024-55727-4.

Biases in COVID-19 vaccine effectiveness studies using cohort design.

Agampodi S, Tadesse B, Sahastrabuddhe S, Excler J, Kim J Front Med (Lausanne). 2024; 11:1474045.

PMID: 39540039 PMC: 11557388. DOI: 10.3389/fmed.2024.1474045.

COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of Rituximab.

Ammitzboll C, Thomsen M, Bartels L, Hansen C, Hermansen M, Hanel M ACR Open Rheumatol. 2024; 6(8):519-528.

PMID: 38923834 PMC: 11319921. DOI: 10.1002/acr2.11681.

References

Pritchard E, Matthews P, Stoesser N, Eyre D, Gethings O, Vihta K . Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021; 27(8):1370-1378. PMC: 8363500. DOI: 10.1038/s41591-021-01410-w. View

Johansson M, Quandelacy T, Kada S, Prasad P, Steele M, Brooks J . SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Netw Open. 2021; 4(1):e2035057. PMC: 7791354. DOI: 10.1001/jamanetworkopen.2020.35057. View

Thompson M, Burgess J, Naleway A, Tyner H, Yoon S, Meece J . Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December.... MMWR Morb Mortal Wkly Rep. 2021; 70(13):495-500. PMC: 8022879. DOI: 10.15585/mmwr.mm7013e3. View

Kojima N, Shrestha N, Klausner J . A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection. Eval Health Prof. 2021; 44(4):327-332. PMC: 8564250. DOI: 10.1177/01632787211047932. View

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View

Gandhi M, Yokoe D, Havlir D . Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020; 382(22):2158-2160. PMC: 7200054. DOI: 10.1056/NEJMe2009758. View

Pulliam J, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome M . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022; 376(6593):eabn4947. PMC: 8995029. DOI: 10.1126/science.abn4947. View

Lopez Bernal J, Gower C, Andrews N . Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. N Engl J Med. 2021; 385(25):e92. DOI: 10.1056/NEJMc2113090. View

Reddy K . Boosters appear effective, but are they always needed?. Lancet. 2021; 398(10316):2055-2057. PMC: 8555972. DOI: 10.1016/S0140-6736(21)02388-6. View

10.

Matheson N, Warne B, Weekes M, Maxwell P . Mass testing of university students for covid-19. BMJ. 2021; 375:n2388. DOI: 10.1136/bmj.n2388. View

11.

Thompson M, Stenehjem E, Grannis S, Ball S, Naleway A, Ong T . Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021; 385(15):1355-1371. PMC: 8451184. DOI: 10.1056/NEJMoa2110362. View

12.

Tenforde M, Olson S, Self W, Talbot H, Lindsell C, Steingrub J . Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(18):674-679. PMC: 9368749. DOI: 10.15585/mmwr.mm7018e1. View

13.

Anderson M, Stec M, Rewane A, Landay A, Cloherty G, Moy J . SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine. JAMA Netw Open. 2021; 4(8):e2119741. PMC: 8346938. DOI: 10.1001/jamanetworkopen.2021.19741. View

14.

Sheikh A, McMenamin J, Taylor B, Robertson C . SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293):2461-2462. PMC: 8201647. DOI: 10.1016/S0140-6736(21)01358-1. View

15.

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

16.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

17.

Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651. PMC: 8848203. DOI: 10.1001/jama.2022.0470. View

18.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

19.

Heinze G, Schemper M . A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001; 57(1):114-9. DOI: 10.1111/j.0006-341x.2001.00114.x. View

20.

Nanduri S, Pilishvili T, Derado G, Soe M, Dollard P, Wu H . Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March.... MMWR Morb Mortal Wkly Rep. 2021; 70(34):1163-1166. PMC: 8389386. DOI: 10.15585/mmwr.mm7034e3. View